These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 37234773)

  • 21. A Novel Prognostic and Predictive Signature for Lung Adenocarcinoma Derived from Combined Hypoxia and Infiltrating Immune Cell-Related Genes in TCGA Patients.
    Wu X; Zhu J; Liu W; Jin M; Xiong M; Hu K
    Int J Gen Med; 2021; 14():10467-10481. PubMed ID: 35002303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor microenvironment related novel signature predict lung adenocarcinoma survival.
    Chen J; Zhou R
    PeerJ; 2021; 9():e10628. PubMed ID: 33520448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and Validation of Lactate Metabolism-Related lncRNA Signature as a Prognostic Model for Lung Adenocarcinoma.
    Mai S; Liang L; Mai G; Liu X; Diao D; Cai R; Liu L
    Front Endocrinol (Lausanne); 2022; 13():829175. PubMed ID: 35422758
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
    Wu P; Zheng Y; Wang Y; Wang Y; Liang N
    J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Guidelines on lung adenocarcinoma prognosis based on immuno-glycolysis-related genes.
    Zhang Y; Qin W; Zhang W; Qin Y; Zhou YL
    Clin Transl Oncol; 2023 Apr; 25(4):959-975. PubMed ID: 36447119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive molecular analyses of a TNF family-based signature with regard to prognosis, immune features, and biomarkers for immunotherapy in lung adenocarcinoma.
    Zhang C; Zhang G; Sun N; Zhang Z; Zhang Z; Luo Y; Che Y; Xue Q; He J
    EBioMedicine; 2020 Sep; 59():102959. PubMed ID: 32853987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Pyroptosis-Related Signature Predicts Overall Survival and Immunotherapy Responses in Lung Adenocarcinoma.
    Zhu K; Yan A; Zhou F; Zhao S; Ning J; Yao L; Shang D; Chen L
    Front Genet; 2022; 13():891301. PubMed ID: 35795208
    [No Abstract]   [Full Text] [Related]  

  • 28. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of a Pyroptosis-Related Gene Signature for Predicting the Immune Status and Prognosis in Lung Adenocarcinoma.
    Gong Z; Li Q; Yang J; Zhang P; Sun W; Ren Q; Tang J; Wang W; Gong H; Li J
    Front Bioeng Biotechnol; 2022; 10():852734. PubMed ID: 35646872
    [No Abstract]   [Full Text] [Related]  

  • 30. Identification and validation of a 4-extracellular matrix gene signature associated with prognosis and immune infiltration in lung adenocarcinoma.
    Chai Y; Ma Y; Feng W; Xiang H; Lu H; Jin L
    Heliyon; 2024 Jan; 10(2):e24162. PubMed ID: 38293522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of pyroptosis-related factors in lung adenocarcinoma.
    Lin X; Zhou T; Hu S; Yang L; Yang Z; Pang H; Zhou X; Zhong R; Fang X; Yu Z; Hu K
    J Thorac Dis; 2022 Mar; 14(3):654-667. PubMed ID: 35399245
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single-cell sequencing analysis and transcriptome analysis constructed the macrophage related gene-related signature in lung adenocarcinoma and verified by an independent cohort.
    Li R; Tong R; Zhang Z; Deng M; Wang T; Hou G
    Genomics; 2022 Nov; 114(6):110520. PubMed ID: 36372305
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Construction and Validation of a Tumor Microenvironment-Based Scoring System to Evaluate Prognosis and Response to Immune Checkpoint Inhibitor Therapy in Lung Adenocarcinoma Patients.
    Huang P; Xu L; Jin M; Li L; Ke Y; Zhang M; Zhang K; Lu K; Huang G
    Genes (Basel); 2022 May; 13(6):. PubMed ID: 35741714
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Classification of Lung Adenocarcinoma Based on Immune Checkpoint and Screening of Related Genes.
    Zhou T; Yang P; Tang S; Zhu Z; Li X; Yang Z; Wu R; Tian X; Li L
    J Oncol; 2021; 2021():5512325. PubMed ID: 34367284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comprehensive analysis of a novel signature incorporating lipid metabolism and immune-related genes for assessing prognosis and immune landscape in lung adenocarcinoma.
    Wang Y; Xu J; Fang Y; Gu J; Zhao F; Tang Y; Xu R; Zhang B; Wu J; Fang Z; Li Y
    Front Immunol; 2022; 13():950001. PubMed ID: 36091041
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Six CT83-related Genes-based Prognostic Signature for Lung Adenocarcinoma.
    Wang Y; Zhang G; Wang R
    Comb Chem High Throughput Screen; 2022; 25(9):1565-1575. PubMed ID: 34259140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of a ferroptosis-based model to predict prognosis, tumor microenvironment, and drug response for lung adenocarcinoma with weighted genes co-expression network analysis.
    Cheng T; Shan G; Yang H; Gu J; Lu C; Xu F; Ge D
    Front Pharmacol; 2022; 13():1072589. PubMed ID: 36467089
    [No Abstract]   [Full Text] [Related]  

  • 38. Analyzing the characteristics of immune cell infiltration in lung adenocarcinoma via bioinformatics to predict the effect of immunotherapy.
    Liao Y; He D; Wen F
    Immunogenetics; 2021 Oct; 73(5):369-380. PubMed ID: 34302518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Construction of an immune-related lncRNA signature pair for predicting oncologic outcomes and the sensitivity of immunosuppressor in treatment of lung adenocarcinoma.
    Zhuang J; Chen Z; Chen Z; Chen J; Liu M; Xu X; Liu Y; Yang S; Hu Z; He F
    Respir Res; 2022 May; 23(1):123. PubMed ID: 35562727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor necrosis factor-related lncRNAs predict prognosis and immunotherapy response for patients with lung adenocarcinoma.
    Chen JH; Wu X; Wang ZM; Liu ZY; He BX; Song WP; Zhang WZ
    J Thorac Dis; 2023 Mar; 15(3):1373-1386. PubMed ID: 37065578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.